LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 12.

TSMC is poised to gain market share from Samsung, with potential collaborations with US chip giants further strengthening its position. Despite gross margin pressures, TSMC's profitability has exceeded expectations, leading me to upgrade my long term gross margin outlook to 57%-59%. Reduced geopolitical risks and attractive valuations suggest potential for multiple expansion, making a compelling case for undervaluation of TSM stock.

Alibaba Group (NYSE:BABA ) Q4 2025 Earnings Conference Call May 15, 2025 7:30 AM ET Company Participants Lydia Liu - Head of Investor Relations Eddie Wu - Chief Executive Officer Toby Xu - Chief Financial Officer Jiang Fan - Chief Executive Officer of Alibaba E-Commerce Business Group Conference Call Participants Gary Yu - Morgan Stanley Alex Yao - JPMorgan Ronald Keung - Goldman Sachs Kenneth Fong - UBS Joyce Ju - Bank of America Alicia Yap - Citigroup Operator Good day, ladies and gentlemen. Thank you for standing by.

Investors need to pay close attention to BWEN stock based on the movements in the options market lately.

CLB struggles with a 4.4% revenue decline, low ROIC in the first quarter of 2025, minimal dividends and vulnerability to oil price volatility and geopolitical instability.

Exelon (EXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Equity investors continue wondering when small-cap stocks and ETFs will finally garner some momentum. That moment could be nearing.

Microsoft Corporation NASDAQ: MSFT and OpenAI have announced that they are looking to reset their partnership. The reset is the latest chapter in a story that's been building between the two companies for the last six years.

Walmart Inc (NYSE:WMT) stock is falling this morning, last seen 3.8% lower at $93.20 even after the retail giant beat quarterly earnings expectations and delivered its first-ever profitable quarter for e-commerce operations.

While the top- and bottom-line numbers for Nice (NICE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Although the revenue and EPS for Telus (TU) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The headline numbers for Deere (DE) give insight into how the company performed in the quarter ended April 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

While the top- and bottom-line numbers for Walmart (WMT) give a sense of how the business performed in the quarter ended April 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.